Skip to Main Content

Paper Details

A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery.
Eur J Cancer
7
2022
Author NameAffiliation
Bartosz ChmielowskiJonsson Comprehensive Cancer Center, University of California Los Angeles
Hussein A TawbiUniversity of Texas MD Anderson Cancer Center
  • 1 - 2

Datasets

Release 1.2